These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 33177386)

  • 41. Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia.
    Saiyed M; Byrnes J; Srivastava T; Scuffham P; Downes M
    Clin Drug Investig; 2020 Dec; 40(12):1167-1176. PubMed ID: 33140194
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
    Hiraoka A; Kumada T; Kariyama K; Tada T; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M;
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1812-1819. PubMed ID: 33171524
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
    Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
    PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
    Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
    Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
    Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
    BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy.
    Hua Y; Sun Z; Xiao Y; Li H; Ma X; Luo X; Tan W; Xie Z; Zhang Z; Tang C; Zhuang H; Xu W; Zhu H; Chen Y; Shang C
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39029924
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center.
    Ng KYY; Wong LWJ; Ang AJS; Tan SH; Choo SP; Tai DW; Lee JJX
    Asia Pac J Clin Oncol; 2021 Oct; 17(5):e249-e261. PubMed ID: 32875742
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis.
    Dong D; Shi JY; Shang X; Liu B; Xu WL; Cui GZ; Wang NY
    Medicine (Baltimore); 2022 Feb; 101(5):e28680. PubMed ID: 35119010
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
    Kuo YH; Wang JH; Hung CH; Rau KM; Wu IP; Chen CH; Kee KM; Hu TH; Lu SN
    J Gastroenterol Hepatol; 2017 Dec; 32(12):1975-1981. PubMed ID: 28295594
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.
    Wu CJ; Lee PC; Hung YW; Lee CJ; Chi CT; Lee IC; Hou MC; Huang YH
    Cancer Immunol Immunother; 2022 Nov; 71(11):2631-2643. PubMed ID: 35347395
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study.
    Tajiri K; Tokimitsu Y; Kawai K; Motofuji Y; Shinno E; Kashii Y; Muraishi N; Murayama A; Hayashi Y; Minemura M; Takahara T; Shimizu Y; Yasuda I
    Anticancer Res; 2022 Dec; 42(12):6007-6018. PubMed ID: 36456142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis.
    Casadei-Gardini A; Scartozzi M; Tada T; Yoo C; Shimose S; Masi G; Lonardi S; Frassineti LG; Nicola S; Piscaglia F; Kumada T; Kim HD; Koga H; Vivaldi C; Soldà C; Hiraoka A; Bang Y; Atsukawa M; Torimura T; Tsuj K; Itobayashi E; Toyoda H; Fukunishi S; Rimassa L; Rimini M; Cascinu S; Cucchetti A
    Liver Int; 2021 Jun; 41(6):1389-1397. PubMed ID: 33547848
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.
    Shimose S; Kawaguchi T; Iwamoto H; Tanaka M; Miyazaki K; Ono M; Niizeki T; Shirono T; Okamura S; Nakano M; Suga H; Yamaguchi T; Yokokura Y; Noguchi K; Koga H; Torimura T
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32295043
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma.
    Peng TR; Wu CC; Chang SY; Chen YC; Wu TW; Hsu CS
    Int Immunopharmacol; 2022 Nov; 112():109223. PubMed ID: 36084538
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
    Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
    J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis.
    Wang XH; Liu CJ; Wen HQ; Duan XH; Jiao YQ; Liu YJ; Chen MS; Zhu KS; Mao XH; Zhou QF
    Clin Transl Med; 2023 Mar; 13(3):e1214. PubMed ID: 36855781
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor for treating unresectable hepatocellular carcinoma.
    Bai Z; Yu X; Tang Q; Zhang R; Shi X; Liu C
    Br J Hosp Med (Lond); 2024 Jul; 85(7):1-12. PubMed ID: 39078898
    [No Abstract]   [Full Text] [Related]  

  • 60. Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
    Cai H; Zhang L; Li N; Zheng B; Liu M
    J Comp Eff Res; 2020 Jun; 9(8):553-562. PubMed ID: 32419473
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.